KENILWORTH, N.J., Aug. 17 /PRNewswire-FirstCall/ -- Schering-Plough Corporation announced today clarification on its question regarding the expiration date for its rights to market golimumab worldwide, excluding the United States, Japan and certain other Asian markets. As announced in August 2005, Schering-Plough and Centocor, Inc. stated that they were working together to move forward with their collaboration on golimumab and were taking steps to resolve the difference of opinion as to the expiration date.
Schering-Plough’s rights to market golimumab will extend to 15 years after the first commercial sale in its territories. The Company aspires to launch golimumab in 2009 or 2010.
Developed by Centocor and Schering-Plough, golimumab is a fully-human monoclonal antibody being developed as a treatment for certain immune-mediated inflammatory diseases. Golimumab is currently being investigated in Phase III trials for the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
Schering-Plough is a global science-based health care company with leading prescription, consumer and animal health products. Through internal research and collaborations with partners, Schering-Plough discovers, develops, manufactures and markets advanced drug therapies to meet important medical needs. Schering-Plough’s vision is to earn the trust of the physicians, patients and customers served by its more than 32,000 people around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com.
SCHERING-PLOUGH DISCLOSURE NOTICE: This press release contains certain “forward-looking statements” within the meaning of the Securities Litigation Reform Act of 1995, including statements related to the potential market for golimumab and the company’s strategy. Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward-looking statement. Many factors could cause actual results to differ materially from Schering-Plough’s forward- looking statements, including market forces, economic factors, product availability, current and future branded, generic or over-the-counter competition and the regulatory process, among other uncertainties. For further details about these and other factors that may impact the forward-looking statements, see Schering-Plough’s Securities and Exchange Commission filings, including Part II Item 1A of the 10-Q for the second quarter 2006.
72-0806
Schering-Plough Corporation
CONTACT: Media, Rosemarie Yancosek, +1-908-298-7476, or Investors, AlexKelly, +1-908-298-7436, both of Schering-Plough Corporation
Web site: http://www.schering-plough.com//
Company News On-Call: http://www.prnewswire.com/comp/777050.html /
